The ease of access to genetic testing as the first line investigation for neurometabolic disorders has been increasing; however, the orexin measurements could be a good candidate as a biomarker for accurate diagnosis, clinical evaluation with proper treatments, and approach to pathophysiology of narcolepsy-cataplexy and cholesterol metabolism. The gene discussed is HCRT; the disease is narcolepsy-cataplexy syndrome.